Loading stock data…
$2.50-0.21 (-7.86%)
PAVmed Inc.
PAVmed Inc. in the Healthcare sector is trading at $2.50 with a market capitalization of $39M. Wall Street consensus targets $36.50 (2 analysts), implying a +1360.0% move over the next 12 months. The stock is currently near its 52-week low of $2.50, remaining 63.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33,000↑ | $22,000↓ | $52,000↑ | $5,000↓ | $6,000 |
| Gross Profit | -$89,000↓ | -$75,000↓ | -$33,000↑ | -$50,000↓ | -$35,000 |
| Operating Income | -$6.71M↑ | -$7.87M↓ | -$6.65M↓ | -$4.68M↓ | -$4.63M |
| Net Income | -$5.38M↓ | -$60,000↑ | -$1.26M↑ | -$5.38M↑ | -$11.92M |
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for u...